Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Blood (2024) 144 (Supplement 1): 5170.5.

https://doi.org/10.1182/blood-2024-211053

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Abdullah Mohammad Khan, Mehak M Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyoung Tiger, Hira Shaikh, Christopher Strouse, Kimberly M Green, James A Davis, Hamza Hashmi, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend

Blood (2024) 144 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2024-209283

Published: 2024

Journal Articles

Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience

Gray Magee, Razan Mansour, Mark Chang, Shebli Atrash, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Al-Ola Abdallah, Barry Paul, Kimberly M Green, James A Davis, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 7034.

https://doi.org/10.1182/blood-2024-208085

Published: 2024

Journal Articles

Outcomes of Patients with Newly Diagnosed Myeloma Both Transplant Eligible and Ineligible in North Africa: A Usmirc- Morocco/Tunisia Collaboration

Nesrine Ben Sayed, Yosra Ben Youssef, Abederrahim Khélif, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Joseph P. McGuirk, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Houda Masrar, Kamal Doghmi, El Mehdi Mahtat

Blood (2024) 144 (Supplement 1): 7023.

https://doi.org/10.1182/blood-2024-206259

Published: 2024

Journal Articles

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Yara Shatnawi, Zainab Motiwala, Faiz Anwer, Danai Dima, Louis S Williams, Nausheen Ahmed, Sandra Mazzoni, Jack Khouri, Joslyn Rudoni, Mikhaila Rice, Diana Basali, Christy J. Samaras, Jason Valent, Al-Ola Abdallah, Tara Roy, Beth M. Faiman, Shahzad Raza

Blood (2024) 144 (Supplement 1): 7044.

https://doi.org/10.1182/blood-2024-212202

Published: 2024

Journal Articles

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7860.

https://doi.org/10.1182/blood-2024-210976

Published: 2024

Journal Articles

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Forat Lutfi, Joseph P. McGuirk, Al-Ola Abdallah, Faiz Anwer, Manisha Bhutani, Shebli Atrash

Blood (2024) 144 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2024-205422

Published: 2024

Journal Articles

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

Emily J Casteen, Lauren N Scott, Raeef L Rahman, Zahra Mahmoudjafari, Faiz Anwer, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Al-Ola Abdallah, Shebli Atrash, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7950.

https://doi.org/10.1182/blood-2024-204130

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, Darryl Chang, Barry Paul, Hira Shaikh, Christopher Strouse, Emily Struble, Andrew Vegel, James A Davis, Kimberly M Green, Hamza Hashmi, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Reed Friend

Blood (2024) 144 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2024-208799

Published: 2024

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Fathima Shehnaz Ayoobkhan, Raabia Qureshi, Raeef L Rahman, Zohaa Faiz, Sohaib Irfan, Ahmad Iftikhar, Briha Ansari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shahzad Raza, Hira Shaikh, Forat Lutfi, Shebli Atrash, Joseph P. McGuirk, Hamza Hashmi, Faiz Anwer, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2024-208307

Published: 2024

Journal Articles

Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma

Michael Weise, Shebli Atrash, Briha Ansari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2024-207882

Published: 2024

Journal Articles

Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis

Priyanka Venkatesh, Razan Mansour, Hamid Ehsan, Nausheen Ahmed, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shebli Atrash, Barry Paul

Blood (2024) 144 (Supplement 1): 3317.

https://doi.org/10.1182/blood-2024-207270

Published: 2024

Journal Articles

Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review

Moazzam Shahzad, Hana Qasim, Ben Ponvilawan, Muhammad Kashif Amin, Fizza Zulfiqar, Areeba Ismail, Muhammad Uzair Ishaq, Sohaib Irfan, Abhinav Vyas, Ibrahim Khamees, Rida Ihsan, Sibgha Gull Chaudhary, Iqra Anwar, Nausheen Ahmed, Leyla O. Shune, Al-Ola Abdallah, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7237.

https://doi.org/10.1182/blood-2024-198825

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Efficacy of Ruxolitinib with Corticosteroids in Idiopathic Pneumonia Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience and Systematic Review

Moazzam Shahzad, Muhammad Atif Khan, Muhammad Kashif Amin, Zouina Sarfraz, Fizza Zulfiqar, Hana Qasim, Sibgha Gull Chaudhary, Iqra Anwar, Faiza Humayun Khan, Rajat Bansal, Kyle Brownback, Nausheen Ahmed, Sunil Abhyankar, Joseph P. McGuirk, Anurag Singh, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7380.

https://doi.org/10.1182/blood-2024-200435

Published: 2024

Journal Articles

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Joseph G Bennett, Kamen Kossow, Leah Diebolt, Nicole Twardowski, Jianzheng Wu, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Brian Hess, James A Davis, Al-Ola Abdallah, Nausheen Ahmed, Joseph P. McGuirk, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 6556.

https://doi.org/10.1182/blood-2024-201728

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience

Outcomes of Patients with Newly Diagnosed Myeloma Both Transplant Eligible and Ineligible in North Africa: A Usmirc- Morocco/Tunisia Collaboration

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma

Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis

Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Efficacy of Ruxolitinib with Corticosteroids in Idiopathic Pneumonia Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience and Systematic Review

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only